AstraZeneca cancer drug Imfinzi gets USFDA priority review

AstraZeneca said the USFDA accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer.

New Delhi: British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.

The company said the FDA accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer.

Read Also: AstraZeneca leukemia drug Calquence gets USFDA okay

A final decision is expected in the first quarter of 2020.

Read Also: AstraZeneca CKD anaemia drug Roxadustat shows increased haemoglobin levels in Phase 3 trial